Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meningococcal vaccine groups A C Y W-135 conjugate - Novartis

Next Previous
Drug Profile

Meningococcal vaccine groups A C Y W-135 conjugate - Novartis

Alternative Names: GSK3536820A; MCV4 vaccine; MenACWY-CRM; Menhycia; Menveo; MPSV4 vaccine; Multivalent ACWY vaccine candidate - Novartis

Latest Information Update: 30 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer GSK; Novartis; Tianjin CanSino Biotechnology
  • Class Conjugate vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal infections

Most Recent Events

  • 21 Nov 2024 CanSino Biologics plans to initiate a phase III trial for Meningococcal Meningitis (In volunteers) (NCT06700148)
  • 22 Jul 2024 GSK completes the phase-III MENB REC 2ND GEN-045 (V72_79) trial in Meningococcal infections (In adolescents, Prevention) in USA and Italy (IM), (NCT04318548),
  • 26 Jan 2024 CanSino Biologics plans a phase III trial for Meningococcal infections (Prevention) (IM, Injection), in March 2024 (NCT06226714)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top